Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort-Reference-Cited by-同舟云学术

Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort

Published:2017-12-01 Issue:12 Volume:3 Page:1640
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Mai Phuong L.¹²,Khincha Payal P.¹,Loud Jennifer T.¹,DeCastro Rosamma M.¹,Bremer Renée C.¹,Peters June A.¹,Liu Chia-Ying³,Bluemke David A.³,Malayeri Ashkan A.³,Savage Sharon A.¹

Affiliation:

1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

2. Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

3. Radiology and Imaging Sciences, Clinical Center, Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series;Journal of Pediatric Hematology/Oncology;2024-08-26

2. Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis;European Radiology;2024-07-29

3. Functional evaluation of germline TP53 variants identified in Brazilian families at-risk for Li–Fraumeni syndrome;Scientific Reports;2024-07-26

4. Whole-body MRI in oncology: A comprehensive review;Clinical Imaging;2024-04

5. Whole-Body MRI Screening for Carriers of Germline TP53 Mutations—A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-02-21